This finding is consistent with a report in a mouse model of PNALD where parenteral treatment with an FXR agonist (GW4064) prevented hepatic injury and cholestasis and reversed the suppression of key ATP-binding cassette transporters, yet had no effect on the expression of CYP7A1 16. The gene discussed is ABCA4; the disease is cholestasis.